* feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma * collection of response rate (T-downstaging, pathological complete remission), correlation of responsiveness with EGFR-status
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
31
825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
400mg/m2 week 1, 250mg/m2 week 2-4
Hospital BHB St. Veit/Glan, Surgery
Saint Veit A. D. Glan, Carinthia, Austria
Hospital Wiener Neustadt, Surgery
Wiener Neustadt, Lower Austria, Austria
Paracelsus Medical University Salzburg - Oncology
Salzburg, Salzburg, Austria
feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma
Time frame: descriptive evaluation
collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status
Time frame: description evaluation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medical University of Graz, Oncology
Graz, Styria, Austria
State Hospital Leoben
Leoben, Styria, Austria
Medical University of Innsbruck, Surgery
Innsbruck, Tyrol, Austria
Hospital BHS Linz, Radiooncology
Linz, Upper Austria, Austria
Klinikum Wels-Grieskirchen
Wels, Upper Austria, Austria
Medical University of Vienna, Radiotherapy
Vienna, Vienna, Austria
State Hospital Feldkirch
Feldkirch, Vorarlberg, Austria